BTK and fungal infectious disease: Relevant to these clinical observations, Btk-/- or ibrutinib/acalabrutinib-treated monocytes and macrophages exhibit defective TLR9-, TREM-1 and Dectin-1-mediated phagocytosis in response to fungal infections (24, 163, 169–172).